CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

MVC-COV1901Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug1323 Hydroxychloroquine sulfate Wiki 1.00
drug1605 Lopinavir/ritonavir Wiki 0.32

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901

This is a phase I prospective, open-labeled, single-center study to evaluate the safety and immunogenicity of MVC-COV1901.

NCT04487210 COVID-19 Biological: MVC-COV1901

Primary Outcomes

Description: Incidence of solicited adverse events (AEs) after vaccination, Incidence of unsolicited AEs and other AEs after vaccination, Incidence of laboratory abnormality after vaccination, Incidence of adverse event of special interest (AESI) and serious adverse events (SAEs) after vaccination

Measure: Safety of MVC-COV1901

Time: Day 1 to 28 days after second vaccination

Secondary Outcomes

Description: Geometric mean titer (GMT), Seroconversion rate (SCR), and GMT ratio

Measure: Immunogenicity (neutralizing antibody titers and antigen specific binding antibody titers)

Time: 14 days, 28 days after each vaccination, and 180 days after second vaccination.

Description: The positive rate of cellular mediated immune response

Measure: Immunogenicity (antigen specific cellular immune responses)

Time: 28 days and 180 days after second vaccination

Description: Incidence of other adverse events, Incidence of adverse event of special interest (AESI) and serious adverse events (SAEs) within the study period

Measure: Safety of MVC-COV1901

Time: Day 1 to Day 209

No related HPO nodes (Using clinical trials)